{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T15:31:34Z","timestamp":1648913494270},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1097\/maj.0b013e3181695687","type":"journal-article","created":{"date-parts":[[2008,10,9]],"date-time":"2008-10-09T07:14:53Z","timestamp":1223536493000},"page":"327-329","source":"Crossref","is-referenced-by-count":2,"title":["JAK2 V617F Mutation Testing in Polycythemia Vera: Use and Impact in an Academic Practice"],"prefix":"10.1016","volume":"336","author":[{"suffix":"Jr.","given":"Robert T.","family":"Means","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/MAJ.0b013e3181695687_bb0010","series-title":"Wintrobe\u2019s clinical hematology,","first-page":"2259","article-title":"Polycythemia vera","author":"Means","year":"2003"},{"key":"10.1097\/MAJ.0b013e3181695687_bb0015","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3181695687_bb0020","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1038\/sj.leu.2404379","article-title":"JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?","volume":"20","author":"Verstovsek","year":"2006","journal-title":"Leukemia"},{"key":"10.1097\/MAJ.0b013e3181695687_bb0025","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/ajh.20721","article-title":"Identification of JAK2(V617F) in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera","volume":"82","author":"Ganly","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1097\/MAJ.0b013e3181695687_bb0030","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"10.1097\/MAJ.0b013e3181695687_bb0035","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.V99.4.1144","article-title":"The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members\u2019 practice patterns","volume":"99","author":"Streiff","year":"2002","journal-title":"Blood"},{"key":"10.1097\/MAJ.0b013e3181695687_bb0040","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1055\/s-2006-942754","article-title":"The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders","volume":"32","author":"Michiels","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"10.1097\/MAJ.0b013e3181695687_bb0045","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1182\/blood-2006-12-038968","article-title":"How I treat patients with polycythemia vera","volume":"109","author":"Finazzi","year":"2007","journal-title":"Blood"},{"key":"10.1097\/MAJ.0b013e3181695687_bb0050","series-title":"Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients","author":"Butcher","year":"2007"},{"key":"10.1097\/MAJ.0b013e3181695687_bb0055","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","article-title":"Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"key":"10.1097\/MAJ.0b013e3181695687_bb0060","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood-2007-07-101576","article-title":"Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders","volume":"111","author":"Pietra","year":"2008","journal-title":"Blood"},{"key":"10.1097\/MAJ.0b013e3181695687_bb0065","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2141.2007.06806.x","article-title":"Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera","volume":"139","author":"Scott","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1097\/MAJ.0b013e3181695687_bb0070","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/sj.leu.2404069","article-title":"Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis","volume":"20","author":"James","year":"2006","journal-title":"Leukemia"},{"key":"10.1097\/MAJ.0b013e3181695687_bb0075","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2006-04-017392","article-title":"Involvement of various hematopoietic cell lineages by the JAK2V617F mutation in polycythemia vera","volume":"108","author":"Ishii","year":"2006","journal-title":"Blood"},{"key":"10.1097\/MAJ.0b013e3181695687_bb0080","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2006-10-054940","article-title":"The JAK2 V617F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera","volume":"110","author":"Dupont","year":"2007","journal-title":"Blood"},{"key":"10.1097\/MAJ.0b013e3181695687_bb0085","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3324\/haematol.10660","article-title":"JAK2V617F detection and dosage of serum erythropoietin: first steps of the diagnostic work-up for patients consulting for elevated hematocrit","volume":"92","author":"Girodon","year":"2007","journal-title":"Haematologica"},{"key":"10.1097\/MAJ.0b013e3181695687_bb0090","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1182\/blood-2005-04-1515","article-title":"The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients","volume":"106","author":"Goerttler","year":"2005","journal-title":"Blood"},{"key":"10.1097\/MAJ.0b013e3181695687_bb0095","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2005-08-3395","article-title":"V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis","volume":"107","author":"Campbell","year":"2006","journal-title":"Blood"},{"key":"10.1097\/MAJ.0b013e3181695687_bb0100","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2005.05858.x","article-title":"The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia","volume":"132","author":"Cheung","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1097\/MAJ.0b013e3181695687_bb0105","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/sj.leu.2404755","article-title":"The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis","volume":"21","author":"Pemmaraju","year":"2007","journal-title":"Leukemia"},{"key":"10.1097\/MAJ.0b013e3181695687_bb0110","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-2141.2005.05776.x","article-title":"The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates","volume":"131","author":"Tefferi","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1097\/MAJ.0b013e3181695687_bb0115","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1074\/jbc.C600277200","article-title":"Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth","volume":"282","author":"Li","year":"2007","journal-title":"J Biol Chem"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915321650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915321650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T14:12:09Z","timestamp":1557843129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962915321650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S0002962915321650"],"URL":"https:\/\/doi.org\/10.1097\/maj.0b013e3181695687","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}